Amy Dezern, MD, MHS

Amy Dezern, MD, MHS, closes her discussion by emphasizing the need for more treatments in MDS.

Dr Amy Dezern discusses the FDA priority review for luspatercept in the first-line setting for MDS and how it may impact patients.

Amy Dezern, MD, MHS, explains the importance of proper dose titration for luspatercept in the treatment of MDS.

Dr Amy Dezern reviews the mechanism of action of luspatercept and its rationale for use in MDS.

Amy Dezern, MD, MHS, details her experience with using erythropoiesis stimulating agents for the treatment of MDS in her clinical practice.

Dr Amy Dezern emphasizes how delayed frontline treatment of MDS can impact overall outcomes for patients with MDS.

Amy Dezern, MD, MHS, describes the currently available first-line treatment options for patients with MDS.

Dr Amy Dezern discusses the criteria for subtype classification and risk stratification in patients with MDS.

Amy Dezern, MD, MHS, shares the case of a 70-year-old man with MDS stratified as low-risk using the Revised International Prognostic Scoring System.